Significance of age-associated quality of life in patients with stage IV breast cancer who underwent endocrine therapy in Japan.

In conclusion, psychological stress was more prominent in younger patients with stage IV breast cancer treated with hormonal therapy compared with elderly patients. Importantly, improving QOL within the 3 months after treatment initiation could lead to longer PFS rate. PMID: 32934747 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

ConclusionsThis is a large study of patient preferences on HT. Compared with other studies with similar design, the patients included in the present study required larger benefits to make adjuvant therapy worthwhile.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeGenomic testing in early-stage hormone-positive breast cancer is the standard of care. However, decisions based on genomic testing results are predicated on the assumption that patients receive endocrine treatment. We sought to investigate racial differences in genomic testing and adjuvant treatment in breast cancer.MethodsA retrospective, population-based hospital registry study using the National Cancer Database. Participants included women with stages I –II, ER + breast cancer between 2010 and 2014. Sociodemographic factors were analyzed. Primary outcomes were the utilization of genomi...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusions: Our results reveal an important role of UCH-L1 in modulating ERα status and demonstrate the involvement of UCH-L1-EGFR signaling pathway, suggesting that UCH-L1 may serve as a novel adjuvant target for treatment of hormone therapy-insensitive breast cancers. Targeting UCH-L1 to sensitize ER negative breast cancer to anti-estrogen therapy might represent a new therapeutic strategy that warrants further exploration.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: Our prodrug-based co-delivery system may provide an effective and simple strategy to re-sensitize TNBCs to TAM-based hormone therapy.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
We report the case of a 39-year-old woman with primary breast cancer and associated synchronous bone metastases, who experienced a disease response of 12 years with hormonal therapy as maintenance after first line chemotherapy, with a good toxicity profile. Diagnosis: The patient was diagnosed with estrogen receptor + human epidermal growth factor receptor 2 (HER2)− metastatic breast cancer with synchronous bone metastases. Interventions: This patient was treated with chemotherapy for 6 cycles as a first-line therapy following by endocrine treatment given as a maintenance therapy. Outcomes: Our patient exper...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Abstract Male breast cancer treatment regimens are often extrapolated from female-based studies because of a paucity of literature analyzing male breast cancer. Using ClinicalTrials.gov, we analyzed breast cancer randomized clinical trials (RCTs) to determine which factors were associated with male-gender inclusion. Of 131 breast cancer RCTs identified, male patients represented 0.087% of the total study population, which is significantly less than the proportion of male patients with breast cancer in the U.S. (0.95%; p 
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ns Verhaegh : Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel testing method was reported before that enables measurement of functional signal transduction pathway activity in individual cancer tissue samples, using mRNA levels of target genes of the respective pathway-specific transcription factor. Using this method, 130 primary breast cancer samples were analyzed fro...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsRa ‐223 with hormonal therapy showed possible efficacy in HR+ bone‐dominant breast cancer metastasis, and adverse events were tolerable. We plan to further investigate the clinical application of Ra‐223 in these patients. (NCT02366130).
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
This study aims to evaluate the antitumour activity of tamoxifen (TAM), a major agent of hormonal therapy for breast cancer, in preclinical GBC model. Quantitative real-time PCR was used to investigate mRNA levels. Protein expression was measured by immunohistochemistry and Western blot. Glycolytic levels were measured by glucose consumption and lactic acid measurement. The antitumour activity of TAM alone or with cisplatin was examined with CCK8 assay, colony formation, flow cytometry and in vivo models. The results revealed that ERɑ expression was higher in GBC tissues and predicted poor clinical outcomes. TAM was showe...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hormonal Therapy | Hormones | Japan Health | Psychology | Study